Literature DB >> 27106278

Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis.

Xi Wang1, Yujie Ning1, Lei Yang1, Huan Liu1, Cuiyan Wu1, Sen Wang1, Xiong Guo2.   

Abstract

A large number of studies have provided new insights into the diagnostic value of circulating microRNAs (miRNA) for osteosarcoma (OS), one of the most common primary malignancies in adolescents. However, inconsistent conclusions on the diagnostic performance of various kinds of miRNAs have been made. To assess the true diagnostic value of circulating miRNA for the early detection of OS in this meta-analysis, multiple databases, including PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Technology of Chongqing (VIP), were carefully searched for available studies up to October 30, 2015. The quality of each study was scored using the quality assessment of diagnostic accuracy studies-2 (QUADAS-2). Sensitivity and specificity was pooled using a random-effects model. Positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the curve (AUC) were used to measure the diagnostic values. Subgroup and meta-regression analyses were used to find potential sources of heterogeneity. Publication bias was tested with the Deeks' funnel plot asymmetry test. Eight articles with 741 OS patients and 479 healthy controls were finally included in this meta-analysis. The pooled estimations indicated circulating miRNAs has a high accuracy for diagnosing OS, with sensitivity of 0.94, specificity of 0.80, PLR of 4.75, NLR of 0.07, DOR of 69, and AUC of 0.94. In addition, subgroup and meta-regression analyses revealed that the expression patterns of miRNAs obtained from plasma are more credible diagnostic biomarkers than those from serum. In conclusion, as noninvasive biomarkers, circulating miRNAs have a promising future for the diagnosis of OS in Asian populations.

Entities:  

Keywords:  Circulating microRNAs; Diagnosis; Meta-analysis; Osteosarcoma

Mesh:

Substances:

Year:  2016        PMID: 27106278     DOI: 10.1007/s10238-016-0422-5

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  38 in total

1.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

2.  Analysis of circulating microRNA: preanalytical and analytical challenges.

Authors:  Jennifer S McDonald; Dragana Milosevic; Honey V Reddi; Stefan K Grebe; Alicia Algeciras-Schimnich
Journal:  Clin Chem       Date:  2011-04-12       Impact factor: 8.327

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  MicroRNA regulation by RNA-binding proteins and its implications for cancer.

Authors:  Marieke van Kouwenhove; Martijn Kedde; Reuven Agami
Journal:  Nat Rev Cancer       Date:  2011-08-05       Impact factor: 60.716

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma.

Authors:  Haikang Cai; Hui Zhao; Jie Tang; Haishan Wu
Journal:  J Surg Res       Date:  2014-11-21       Impact factor: 2.192

8.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

9.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

10.  Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma.

Authors:  Feng Lian; Yong Cui; Chenliang Zhou; Kewei Gao; Liwen Wu
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

View more
  6 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  The prognostic role of CD133 expression in patients with osteosarcoma.

Authors:  Nuo Xu; Yijun Kang; Wanchun Wang; Jian Zhou
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

3.  Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.

Authors:  Shaogang Lv; Jian Xue; Chuanyong Wu; Lin Wang; Jing Wu; Shujun Xu; Xiaohui Liang; Jiatao Lou
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

4.  MicroRNAs as a novel class of diagnostic biomarkers for the detection of osteosarcoma: a meta-analysis.

Authors:  Hong Liu; Ping Li; Liang Chen; Chao Jian; Zonghuan Li; Aixi Yu
Journal:  Onco Targets Ther       Date:  2017-11-01       Impact factor: 4.147

Review 5.  Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

Authors:  Lavinia Raimondi; Angela De Luca; Viviana Costa; Nicola Amodio; Valeria Carina; Daniele Bellavia; Pierfrancesco Tassone; Stefania Pagani; Milena Fini; Riccardo Alessandro; Gianluca Giavaresi
Journal:  Oncotarget       Date:  2017-08-03

6.  Signatures of circulating microRNA in four sarcoma subtypes.

Authors:  Hanna Kosela-Paterczyk; Agnieszka Paziewska; Maria Kulecka; Aneta Balabas; Anna Kluska; Michalina Dabrowska; Magdalena Piatkowska; Natalia Zeber-Lubecka; Filip Ambrozkiewicz; Jakub Karczmarski; Michal Mikula; Piotr Rutkowski; Jerzy Ostrowski
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.